S.794 would require Medicare contractors to hold public meetings and disclose the rationale and evidence underlying an LCD at the start of the process.
Several MDx firms recently touted BCBS's Evidence Street opinions on their tests as milestones, and Palmetto GBA's MolDx may soon be using its assessments.
The firm said it expects that Noridian will similarly confirm its draft local coverage determination, bringing coverage for Percepta to around 35 million.
The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.
Palmetto GBA revised a final LCD for comprehensive genomic profiling in lung cancer, and issued similar draft determinations in other cancers.
In a final policy on comprehensive genomic profiling, Palmetto said that approved registries will have to commit to sharing data, among other requirements.
A recent draft local coverage determination from Medicare contractor Noridian is one step along a growth path, according to Veracyte's CEO.
The firm expects the final LCD will go into effect around the beginning of next year, and that three remaining Medicare contractors will soon post draft LCDs for its test.
While undergoing parallel review for its FoundationOne test by the FDA and CMS, the firm will continue to work with its local MACs on reimbursement.
Noridian said it has identified new data that will "significantly impact" its proposed policy on biomarker tests for guiding adjuvant chemotherapy decisions.
Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.
Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.
Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.
In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.